ClinicalTrials.gg
CompletedNCT03875729PROTECTUpdated Apr 24, 2024Results posted

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

A Phase 3 interventional study of teplizumab and Placebo in Type 1 Diabetes Mellitus, sponsored by Provention Bio, Inc.. Completed at 62 sites in 9 countries. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Provention Bio, Inc. (part of Sanofi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.

Enrollment
3rd of 11
328 · median 60
Started
2019
the only one that year
Phase 3
3 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Provention Bio, Inc.

Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 3 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teplizumab

teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing teplizumab in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..

Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.

Read the detailed description

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, multi-center study to evaluate the efficacy and safety of teplizumab, a humanized, anti-CD3 monoclonal antibody, in children and adolescents ages 8 through 17 recently diagnosed with type 1 diabetes (within 6 weeks of diagnosis). Approximately 300 participants will be randomized at a ratio of 2:1 to either the teplizumab group or the placebo group.

Teplizumab or matching placebo will be administered in two courses 6 months apart. Each course of treatment will include daily infusions for 12 days. The total study duration for each participant will be up to 86 weeks.

The primary objective is to determine whether two courses of teplizumab administered 6 months apart slows the loss of β cells and preserves β cell function over 18 months (78 weeks) in children and adolescents 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.

The secondary objectives are to evaluate improvements in key clinical parameters of diabetes management, to determine the safety and tolerability of teplizumab, and to evaluate the pharmacokinetics (PK) and immunogenicity of teplizumab

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • T1D, type 1 diabetes, recent-onset T1D
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is 8 to 17 years of age, inclusive, at the time of randomization/initiation of study drug administration.
  2. Has received a diagnosis of type 1 diabetes (T1D) according to the criteria from the American Diabetes Association.
  3. Is able to be randomized and initiate study drug within 6 weeks (42 days) of the formal T1D diagnosis.
  4. Has a peak stimulated C-peptide of ≥0.2 pmol/mL from a mixed meal tolerance test (MMTT) at screening.
  5. Has a positive result on testing for T1D-related autoantibodies.

Exclusion criteria

Exclusion Criteria:

  1. Has any disease other than T1D with the exception of stable thyroid or celiac disease.
  2. Has an active infection and/or fever.
  3. Has a history of or serologic evidence at screening of current or past infection with (HIV), virus (HBV), or virus (HCV).
  4. An individual who has a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    Teplizumab

    Teplizumab was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days. Each course included: * Day 1: 106 μg/m\^2 * Day 2: 425 μg/m\^2 * Days 3-12: 850 μg/m\^2 Total per course: 9.0 mg/m\^2 The doses of study drug were calculated based on the participant's body surface area (BSA) measured on the first day of each treatment course.

    Biological: teplizumab

  • Placebo comparator
    Placebo

    Placebo was administered via intravenous infusion in two courses, with the first course starting on Day 1 (Week 1) and the second course approximately 6 months later at Day 182 (Week 26). Participants who were unable to receive the second 12-day course due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions were given the second course at approximately 12 months (Week 52 visit). Each course of treatment included daily infusions for 12 days. The placebo solution consisted of the same formulation as the study drug but without teplizumab. Placebo was administered in the same dose volume and by the same treatment schedule as the active drug.

    Biological: Placebo

Interventions

  • Biologicalteplizumab

    Treatment

  • BiologicalPlacebo

    Control

06

What researchers measure

Primary outcomes

  1. Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT)

    The area under the concentration-time curve (AUC) of C-peptide was measured after a 4-hour mixed meal tolerance test (MMTT) and is a measure of endogenous insulin production and β cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test, i.e., AUC was divided by the last blood sample collection time (240 minutes or the last collection time for 4h MMTT).

    Time frame: Baseline to Week 78

Secondary outcomes

  1. Average Daily Exogenous Insulin Use

    The average daily insulin use was calculated based on participants who have at least 3 days of insulin use recorded in the dairy for the Week 78 visit.

    Time frame: Week 78

  2. Change in Glycated Hemoglobin (HbA1c) Levels (%)

    Change in percentage (%) glycated hemoglobin (HbA1c)

    Time frame: Baseline to Week 78

  3. Time in Range for Glycemia Control

    Time in range (%) for glycemia control was assessed using Continuous Glucose Monitoring (CGM). Time in range was defined as daily average percentage of time a participant's glucose is \>= 70 mg/dL and \<=180 mg/dL. Time in range was calculated based on participants who had at least 3 days of CGM data recorded for Week 78 visit with a range of at least 8 hours on a given day.

    Time frame: Week 78

  4. Rate of Clinically Important Hypoglycemic Events

    Rate = clinically important hypoglycemic events/patient-year. A clinically important episode was defined as a blood glucose value of \<54 mg/dL (3.0 mmol/L) (i.e., Level 2 Hypoglycemia, International Hypoglycemia Study Group, 2017) or a hypoglycemia event of severe cognitive impairment requiring external assistance (such as seizure, syncope, severe confusion with or without a confirmatory low blood glucose reading) (i.e., Level 3 Hypoglycemia, International Hypoglycemia Study Group 2017). Event rate was calculated for each participant as number of events / total study follow-up time. Total study follow-up time was calculated as (the date of last study contact - the first dose date + 1)/365.25. The summary is based on the data reported post-baseline in the Hypoglycemic Events Electronic Diary (eDiary).

    Time frame: During the entire study (from the first dose to the last study contact, up to 78 Weeks)

  5. Number of Participants With Adverse Events of Special Interest (AESIs)

    AESIs are defined in the protocol and categories in the statistical analysis plan. Participants with multiple events are counted only once for each preferred term and category.

    Time frame: During the entire study (from the first dose to the last study contact, up to 78 Weeks)

  6. Teplizumab Serum Concentrations

    PK samples were collected prior to dosing except for Day 9 in Course 1. An additional PK sample was collected 45 minutes after infusion on Day 9 in Course 1. Concentration values below Lower Limit of Quantification (2.50 ng/mL) were set to zero for summary statistics. Course 2 day numbers were set relative to the first day of dosing, regardless of normal or modified dosing schedule.

    Time frame: Pre-dose samples collected on Days 1, 4, 9, 12 and 28 for each of the two treatment courses, and one post-dose sample collected on Day 9 during the first treatment course.

  7. Anti-teplizumab Antibody (ADA) Titers After Treatment Courses

    Baseline was defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.

    Time frame: Baseline through 78 Week

  8. Incidence of Anti-drug Antibodies (ADA) After Treatment Courses

    Baseline is defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.

    Time frame: From baseline through Week 78

07

Results

Posted Apr 24, 2024
Limitations and caveats
Enrollment into the study was temporarily suspended due to COronaVIrus Disease of 2019 (COVID-19) pandemic restrictions. Participants who were unable to receive the second 12-day treatment course at 6 months due to COVID-19 pandemic restrictions were given the second course at approximately 12 months (modified dosing schedule).

Participant flow

The first participant was enrolled on April 5, 2019, and the last participant was enrolled on November 4, 2021.

Participant flow — Overall Study
MilestonePlaceboTeplizumab
Started111217
Completed101195
Not completed1022
Withdrew: Adverse event05
Withdrew: Withdrawal by subject811
Withdrew: Pregnancy01
Withdrew: Lost to follow-up05
Withdrew: Personal reasons20

Outcome measures

PrimaryChange in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT)

The area under the concentration-time curve (AUC) of C-peptide was measured after a 4-hour mixed meal tolerance test (MMTT) and is a measure of endogenous insulin production and β cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test, i.e., AUC was divided by the last blood sample collection time (240 minutes or the last collection time for 4h MMTT).

Time frame:
Baseline to Week 78
Reported as:
Least squares mean · pmol/mL
Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT)
pmol/mLPlaceboTeplizumab
Intent-to-treat-0.2112 (-0.2437 to -0.1786)-0.0859 (-0.1090 to -0.0628)
Per Protocol-0.2185 (-0.2501 to -0.1869)-0.0800 (-0.1030 to -0.0570)
Statistical analysis
  • Placebo vs Teplizumab · ANCOVA · p = <0.001 (ITT: The ANCOVA model included treatment, age group at randomization, and baseline C-peptide ln(AUC+1) as independent variables. Missing data at Week 78 were multiply imputed using pattern-mixture model under the missing not at random assumption.) · Mean difference (net): 0.1253 · 95% CI 0.0852 to 0.1653Least squares mean (LSmean) difference = Teplizumab - Placebo
  • Placebo vs Teplizumab · ANCOVA · p = <0.001 (PP: The ANCOVA model included treatment, age group at randomization, and baseline C-peptide ln(AUC+1) as independent variables. Missing data at Week 78 were multiply imputed using a pattern-mixture model under the missing not at random assumption.) · Mean difference (net): 0.1385 · 95% CI 0.0994 to 0.1776Least squares mean (LSmean) difference = teplizumab - placebo
SecondaryAverage Daily Exogenous Insulin Use

The average daily insulin use was calculated based on participants who have at least 3 days of insulin use recorded in the dairy for the Week 78 visit.

Time frame:
Week 78
Reported as:
Least squares mean · Units/kg/day
Average Daily Exogenous Insulin Use
Units/kg/dayPlaceboTeplizumab
Intent-to-treat0.593 (0.470 to 0.716)0.463 (0.363 to 0.562)
Per Protocol0.613 (0.538 to 0.687)0.446 (0.390 to 0.502)
Statistical analysis
  • Placebo vs Teplizumab · ANCOVA · p = 0.085 (ITT: ANCOVA model included treatment, age group at randomization, and screening peak C-peptide category as independent variables. Missing data at Week 78 were multiply imputed using a pattern-mixture model under the missing not at random assumption.) · Mean difference (final values): -0.131 · 95% CI -0.280 to 0.018LSmean difference = teplizumab - placebo.
  • Placebo vs Teplizumab · ANCOVA · p = <0.001 (PP: ANCOVA model included treatment, age group at randomization, and screening peak C-peptide category as independent variables. Missing data at Week 78 were multiply imputed using a pattern-mixture model under the missing not at random assumption.) · Mean difference (final values): -0.167 · 95% CI -0.256 to -0.078LSmean difference = teplizumab - placebo.
SecondaryChange in Glycated Hemoglobin (HbA1c) Levels (%)

Change in percentage (%) glycated hemoglobin (HbA1c)

Time frame:
Baseline to Week 78
Reported as:
Least squares mean · Percentage of glycated hemoglobin
Change in Glycated Hemoglobin (HbA1c) Levels (%)
Percentage of glycated hemoglobinPlaceboTeplizumab
Intent-to-treat-1.89 (-2.16 to -1.62)-1.98 (-2.17 to -1.78)
Per Protocol-1.94 (-2.21 to -1.67)-2.07 (-2.27 to -1.87)
Statistical analysis
  • Placebo vs Teplizumab · ANCOVA · p = 0.606 (ITT: ANCOVA model included treatment, age group at randomization, screening peak C-peptide category, baseline HbA1c as independent variables. Missing data were multiply imputed using a pattern-mixture model under the missing not at random assumption.) · Mean difference (final values): -0.09 · 95% CI -0.42 to 0.24
  • Placebo vs Teplizumab · ANCOVA · p = 0.454 (PP: ANOVA model included treatment, age group at randomization, screening peak C-peptide category, baseline HbA1c as independent variables. Missing data were multiply imputed using a pattern-mixture model under the missing not at random assumption.) · Mean difference (final values): -0.13 · 95% CI -0.46 to 0.20LSmean difference = teplizumab - placebo.
SecondaryTime in Range for Glycemia Control

Time in range (%) for glycemia control was assessed using Continuous Glucose Monitoring (CGM). Time in range was defined as daily average percentage of time a participant's glucose is \>= 70 mg/dL and \<=180 mg/dL. Time in range was calculated based on participants who had at least 3 days of CGM data recorded for Week 78 visit with a range of at least 8 hours on a given day.

Time frame:
Week 78
Reported as:
Least squares mean · Percentage of time in range
Time in Range for Glycemia Control
Percentage of time in rangePlaceboTeplizumab
Intent-to-treat62.65 (57.38 to 67.92)67.36 (63.70 to 71.03)
Per Protocol61.44 (56.50 to 66.38)67.61 (64.09 to 71.14)
Statistical analysis
  • Placebo vs Teplizumab · ANCOVA · p = 0.151 (ITT: The ANCOVA model included treatment, age group at randomization, and screening peak C-peptide category as independent variables. Missing data were multiply imputed using a pattern-mixture model under the missing not at random assumption.) · Mean difference (final values): 4.71 · 95% CI -1.72 to 11.15LSmean difference = teplizumab - placebo.
  • Placebo vs Teplizumab · ANCOVA · p = 0.045 (PP: The ANCOVA model included treatment, age group at randomization, and screening peak C-peptide category as independent variables. Missing data were multiply imputed using a pattern-mixture model under the missing not at random assumption.) · Mean difference (final values): 6.17 · 95% CI 0.13 to 12.22LSmean difference = teplizumab - placebo.
SecondaryRate of Clinically Important Hypoglycemic Events

Rate = clinically important hypoglycemic events/patient-year. A clinically important episode was defined as a blood glucose value of \<54 mg/dL (3.0 mmol/L) (i.e., Level 2 Hypoglycemia, International Hypoglycemia Study Group, 2017) or a hypoglycemia event of severe cognitive impairment requiring external assistance (such as seizure, syncope, severe confusion with or without a confirmatory low blood glucose reading) (i.e., Level 3 Hypoglycemia, International Hypoglycemia Study Group 2017). Event rate was calculated for each participant as number of events / total study follow-up time. Total study follow-up time was calculated as (the date of last study contact - the first dose date + 1)/365.25. The summary is based on the data reported post-baseline in the Hypoglycemic Events Electronic Diary (eDiary).

Time frame:
During the entire study (from the first dose to the last study contact, up to 78 Weeks)
Reported as:
Mean · Events/patient-year
Rate of Clinically Important Hypoglycemic Events
Events/patient-yearPlaceboTeplizumab
Intent-to-treat4.24 (3.06 to 5.89)4.68 (3.70 to 5.91)
Per protocol4.63 (3.31 to 6.49)5.04 (3.94 to 6.44)
Statistical analysis
  • Placebo vs Teplizumab · Negative binomial regression model · p = 0.634 (ITT: Estimates and p-values were obtained from a negative binomial regression model using rate of hypoglycemic episodes as dependent variable and treatment, age group at randomization, and screening peak C-peptide category as independent variables.) · Rate ratio: 1.10 · 95% CI 0.74 to 1.64Rate ratio = teplizumab / placebo.
  • Placebo vs Teplizumab · Rate ratio · p = 0.690 (PP: Estimates and p-values were obtained from a negative binomial regression model using rate of hypoglycemic episodes as dependent variable and treatment age group at randomization, and screening peak C-peptide category as independent variables.) · Rate ratio: 1.09 · 95% CI 0.72 to 1.65Rate ratio = teplizumab / placebo.
SecondaryNumber of Participants With Adverse Events of Special Interest (AESIs)

AESIs are defined in the protocol and categories in the statistical analysis plan. Participants with multiple events are counted only once for each preferred term and category.

Time frame:
During the entire study (from the first dose to the last study contact, up to 78 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)
ParticipantsPlaceboTeplizumab
Treatment-emergent AESI2463
Participants with at least one >= grade 3 infection21
Participants with at least one acute mononucleosis-like illness317
Participants with at least one lymphoma or other malignancy, including benign tumors12
Participants with at least one instance of severe hypoglycemic event1829
Participants with at least one >=grade 3 liver function abnormality08
Participants with at least one >= grade 3 thrombocytopenia00
Participants with at least one >= grade 3 neutropenia07
Participants with at least one >= grade 4 allergic/hypersensitivity reaction00
Participants with at least one >= grade 3 rash04
SecondaryTeplizumab Serum Concentrations

PK samples were collected prior to dosing except for Day 9 in Course 1. An additional PK sample was collected 45 minutes after infusion on Day 9 in Course 1. Concentration values below Lower Limit of Quantification (2.50 ng/mL) were set to zero for summary statistics. Course 2 day numbers were set relative to the first day of dosing, regardless of normal or modified dosing schedule.

Time frame:
Pre-dose samples collected on Days 1, 4, 9, 12 and 28 for each of the two treatment courses, and one post-dose sample collected on Day 9 during the first treatment course.
Reported as:
Geometric mean · ng/mL
Teplizumab Serum Concentrations
ng/mLTeplizumab
Course 1, Day 17.4271 ± 628.114
Course 1, Day 470.4769 ± 50.767
Course 1, Day 9250.3928 ± 44.677
Course 1, Day 9 post-dose636.4390 ± 33.171
Course 1, Day 12305.6569 ± 47.048
Course 1, Day 2825.0317 ± 79.953
Course 2, Day 15.5433 ± 522.457
Course 2, Day 482.0166 ± 50.333
Course 2, Day 9145.9498 ± 75.737
Course 2, Day 12108.2988 ± 107.776
Course 2, Day 2813.2159 ± 181.421
SecondaryAnti-teplizumab Antibody (ADA) Titers After Treatment Courses

Baseline was defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.

Time frame:
Baseline through 78 Week
Reported as:
Geometric mean · Titer
Anti-teplizumab Antibody (ADA) Titers After Treatment Courses
TiterTeplizumab
Baseline65.81 ± 182.3
Week 2177.22 ± 278.2
Week 4817.08 ± 275.0
Week 81040.58 ± 239.1
Week 26 Day 182834.86 ± 226.1
Week 26 Day 187807.26 ± 681.6
Week 279257.15 ± 222.3
Week 309985.29 ± 218.7
Week 347326.91 ± 237.0
Week 393701.64 ± 202.8
Week 52 Day 3641398.22 ± 240.1
Week 52 Day 369308.80 ± 207.5
Week 538043.22 ± 165.7
Week 5614221.44 ± 241.8
Week 609040.49 ± 299.4
Week 65996.15 ± 484.4
Week 78672.13 ± 332.4
SecondaryIncidence of Anti-drug Antibodies (ADA) After Treatment Courses

Baseline is defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.

Time frame:
From baseline through Week 78
Reported as:
Count of participants · Participants
Incidence of Anti-drug Antibodies (ADA) After Treatment Courses
ParticipantsTeplizumab
Baseline — Positive15
Baseline — Negative200
Week 2 — Positive182
Week 2 — Negative25
Week 4 — Positive178
Week 4 — Negative26
Week 8 — Positive175
Week 8 — Negative31
Week 26 Day 182 — Positive139
Week 26 Day 182 — Negative53
Week 26 Day 187 — Positive130
Week 26 Day 187 — Negative40
Week 27 — Positive167
Week 27 — Negative8
Week 30 — Positive169
Week 30 — Negative7
Week 34 — Positive163
Week 34 — Negative13
Week 39 — Positive170
Week 39 — Negative22
Week 52 Day 364 — Positive155
Week 52 Day 364 — Negative37
Week 52 Day 369 — Positive11
Week 52 Day 369 — Negative4
Week 53 — Positive15
Week 53 — Negative1
Week 56 — Positive18
Week 56 — Negative1
Week 60 — Positive17
Week 60 — Negative1
Week 65 — Positive153
Week 65 — Negative38
Week 78 — Positive146
Week 78 — Negative45

Adverse events

Collected over Treatment-emergent adverse events = from the first dose of study drug administration through the end of the study, up to 78 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/111 (0%)6/111 (5.4%)88/111 (79.3%)
Teplizumab0/217 (0%)12/217 (5.5%)212/217 (97.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboTeplizumab
GastroenteritisInfections and infestations2/1110/217
Cytokine release syndromeImmune system disorders0/1113/217
Suicidal ideationPsychiatric disorders0/1112/217
SyncopeNervous system disorders1/1110/217
ConstipationGastrointestinal disorders1/1110/217
AnxietyPsychiatric disorders1/1110/217
Device related bacteraemiaInfections and infestations1/1110/217
HypoglycaemiaMetabolism and nutrition disorders1/1111/217
ConcussionInjury, poisoning and procedural complications0/1111/217
PalpitationCardiac disorders0/1111/217
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlaceboTeplizumab
HypoglycaemiaMetabolism and nutrition disorders81/111151/217
HeadacheNervous system disorders21/11194/217
NauseaGastrointestinal disorders21/11192/217
RashSkin and subcutaneous tissue disorders5/11186/217
Lymphocyte count decreasedInvestigations5/11173/217
VomitingGastrointestinal disorders15/11168/217
PyrexiaGeneral disorders11/11153/217
White blood cell count decreasedInvestigations6/11153/217
COVID-19Infections and infestations26/11149/217
LymphopeniaBlood and lymphatic system disorders0/11150/217

Baseline characteristics

Intent-to-treat population

Age, Categorical
Age, Categorical(Participants)PlaceboTeplizumabTotal
<=18 years111217328
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)PlaceboTeplizumabTotal
Mean12.3 ± 2.5512.0 ± 2.5312.1 ± 2.54
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTeplizumabTotal
Female4298140
Male69119188
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTeplizumabTotal
Hispanic or Latino41418
Not Hispanic or Latino101193294
Unknown or Not Reported61016
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTeplizumabTotal
White94189283
Black or African American6511
Asian347
American Indian or Alaskan Native011
Native Hawiian or Other Pacific Islander101
Multiple066
Other145
Not reported6814
Region of Enrollment
Region of Enrollment(participants)PlaceboTeplizumabTotal
Canada71320
Belgium415
United States56126182
Czechia101727
Poland153348
United Kingdom6612
France5914
Germany81220
Peak C-peptide at screening
Peak C-peptide at screening(Participants)PlaceboTeplizumabTotal
0.2 - 0.7 pmol/mL4791138
>0.7 pmol/mL64126190
Age group at randomization
Age group at randomization(Participants)PlaceboTeplizumabTotal
8 - 12 years62120182
>12 - 17 years4997146

17 further baseline measures are reported on the registry.

08

Study locations

62 sites
  • Rady Children's Hospital-San Diego (Site 004)
    San Diego, California 92123, United States
  • UCSF Medical Center (Site 001)
    San Francisco, California 94158, United States
  • Diablo Clinical Research, Inc. (Site 002)
    Walnut Creek, California 94598, United States
  • University of Colorado-Barbara Davis Center for Childhood Diabetes (Site 005)
    Aurora, Colorado 80045, United States
  • Yale University of Medicine (Site 020)
    New Haven, Connecticut 06520, United States
  • UF Clinical and Translation Research Building (Site 015)
    Gainesville, Florida 32610, United States
  • Nemours Children's Specialty Care-Endocrinology (Site 047)
    Jacksonville, Florida 32207, United States
  • University of Miami Health System (Site 028)
    Miami, Florida 33136, United States
  • All Children's Hospital-Johns Hopkins Medicine (Site 048)
    Saint Petersburg, Florida 33701, United States
  • University of South Florida Diabetes and Endocrinology Center (Site 011)
    Tampa, Florida 33612, United States
  • Atlanta Diabetes Associates (Site 009)
    Atlanta, Georgia 30318, United States
  • Centricity Research (Site 006)
    Columbus, Georgia 31904, United States
  • St. Luke's Children's Endocrinology (Site 052)
    Boise, Idaho 82712, United States
  • Rocky Mountain Diabetes and Osteoporosis Center (Site 007)
    Idaho Falls, Idaho 83404, United States
  • University of Chicago Medical Center (Site 017)
    Chicago, Illinois 60637, United States
  • Indiana University Hospital and Riley Hospital for Children (Site 014)
    Indianapolis, Indiana 46202, United States
  • U. Iowa Children's Hospital (Site 023)
    Iowa City, Iowa 52242, United States
  • Capital Diabetes & Endocrine Associates (Site 029)
    Camp Springs, Maryland 20746, United States
  • Baystate Pediatric Endocrinology & Diabetes (Site 040)
    Springfield, Massachusetts 01199, United States
  • U. Minnesota Health Clinical Research Unit (Site 031)
    Minneapolis, Minnesota 55454, United States
  • Children's Mercy Hospitals & Clinics (Site 026)
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine (Site 018)
    Saint Louis, Missouri 63110, United States
  • Women and Children's Hospital of Buffalo (Site 010)
    Buffalo, New York 14203, United States
  • UNC Hospitals Children's Specialty Clinic (Site 038)
    Chapel Hill, North Carolina 27599, United States
  • Rainbow Babies & Children's Hospital (Site 049)
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic (Site 051)
    Cleveland, Ohio 44195, United States
  • Endocrinology Service Northwest, LLC (Site 034)
    Bend, Oregon 97702, United States
  • Childrens Hospital of Philadelphia - Endocrinology (Site 021)
    Philadelphia, Pennsylvania 19104, United States
  • Sanford Diabetes and Thyroiid Clinical (Site 013)
    Sioux Falls, South Dakota 57105, United States
  • AM Diabetes & Endocrinology Center (Site 008)
    Bartlett, Tennessee 38133, United States
  • Vanderbilt University Medical Center (Site 024)
    Nashville, Tennessee 37232, United States
  • Children's Medical Center Dallas (Site 033)
    Dallas, Texas 75235, United States
  • Benaroya Research Institute at Virginia Mason (Site 016)
    Seattle, Washington 98101, United States
  • MultiCare Institute for Research & Innovation (Site 003)
    Tacoma, Washington 98405, United States
  • UZ Brussel - Campus Jette (Site 202)
    Bruxelles, Brussels Capital Region 1090, Belgium
  • UZ Gent (Site 206)
    Gent, Oost-Vlaanderen 9000, Belgium
  • CHU UCL Namur, site Clinique Sainte-Elisabeth (Site 205)
    Namur, 5000, Belgium
  • Alberta Diabetes Institute Clinical Research Unit Li Ka Shing Centre for Health Research Innovation (Site 103)
    Edmonton, Alberta T6G 2J3, Canada
  • BC Diabetes (Site 102)
    Vancouver, British Columbia, Canada
  • Montreal Children's Hospital-McGill (Site 101)
    Montreal, Quebec, Canada
  • Fakultni nemocnice v Motole (Site 301)
    Praha 5, 150 06, Czechia
  • Hopitaux Pediatriques de Nice CHU-Lenval service de diabetologie et d'endocrinologia (Site 508)
    Nice, Alpes-Maritimes 6200, France
  • CHU Hopital de la Timone-Hopital d'Enfants (Site 512)
    Marseille, Bouces-du-Rhone 13005, France
  • CHU DIJON hopital d'enfant (Site 504)
    Dijon Cedex, cote-d'Or 21079, France
  • Groupe Hospitalier Necker Enfants Malades (site 502)
    Paris, Ile-de-France 75015, France
  • Centre Hospitalier Regional (CHR) d'Orleans-Service de pediatrie (Site 513)
    Orleans, Loiret 45100, France
  • Groupe hospitalier Est-Hopital Femme, Mere, Enfant (Site 509)
    Bron Cedex, Rhone 69677, France
  • Centre hospitalier de Pau (Site 501)
    Pau cedex, 64046, France
  • Universitätsklinikum Freiburg (Site 603)
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Universitätsklinikum Heidelberg (Site 608)
    Heidelberg, Baden-Wurtternberg 69120, Germany
  • Universitätsklinikum Augsburg (Site 606)
    Augsburg, Bayem 86156, Germany
  • Evangelisches Klinikum Bethel Kinderklinik (Site 602)
    Bielefeld, Nordrhein-Westfalen 33617, Germany
  • Universitatsklinikum Carl Gustav Carus (Site 601)
    Dresden, Sachson -1307, Germany
  • Kinderkrankenhaus Auf Der Bult (Site 604)
    Hannover, 30173, Germany
  • Békés Megyei Központi Kórház Pándy Kálmán Tagkórház ( Site 705)
    Gyula, Hungary
  • Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu (Site 804)
    Warszawa, Mazowieckie 01-184, Poland
  • Instytut Diabetologii Sp. z o.o. (Site 802)
    Warszawa, 02-117, Poland
  • Instytut "Pomnik - Centrum Zdrowia Dziecka" (Site 801)
    Warszawa, 04-730, Poland
  • Uniwersyteckie Centrum Kliniczne (Site 803)
    Warszawa, 80-952, Poland
  • Northwick Park Hospital - Paediatrics (site 904)
    London, City Of London HA1 3UJ, United Kingdom
  • Cardiff and Vale NHS Trust - University Hospital of Wales (Site 902)
    Cardiff, CF14 4XN, United Kingdom
  • Sheffield Children's NHS Foundation Trust Western Bank (Site 903)
    Sheffield, s10 2TH, United Kingdom
09

References and documents

Publications

  • Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC; PROTECT Study Investigators. Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med. 2023 Dec 7;389(23):2151-2161. doi: 10.1056/NEJMoa2308743. Epub 2023 Oct 18. PubMed 37861217 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient levels data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After drug approval

Access criteria: Qualified researchers

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in May 2023, 48 months.

Results were first posted in Apr 2024, 11 months after primary completion.

Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 48 months is above that.

Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2019
First posted
Mar 15, 2019
StartActual
Apr 5, 2019
Primary completionActual
May 1, 2023
CompletionActual
May 1, 2023
Results first posted
Apr 24, 2024
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03875729
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Apr 5, 2019
Primary completion
May 1, 2023
Completion
May 1, 2023
Results posted
Apr 24, 2024
Last update
Apr 24, 2024

Study contacts

Chief Medical Officer, MD
study director · Provention Bio, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion